FGFR2 Gene Amplification - stomachcancertrial.com
FGFR2b Overexpression and FGFR2 Gene Amplification in Patients with Advanced Gastric and GEJ Cancer. About 10% of patients with gastric or gastroesophageal junction (GEJ) cancer have FGFR2 (fibroblast growth factor receptor 2) gene-amplified tumors that overexpress FGFR2b protein.
Neratinib HER Mutation Basket Study ... - ClinicalTrials.gov
This is an open-label, multicenter, multinational, Phase 2 study exploring the efficacy and safety of neratinib therapy in patients with solid tumors with activating HER2, HER3 or EGFR mutations or with EGFR gene amplification.
HER2 Status: Tests, Treatments, and More - breastcancer.org
HER2 (human epidermal growth factor receptor 2) is a gene that can play a role in the development of breast cancer.Your pathology report should include information about HER2 status, which tells you whether or not HER2 is playing a role in the cancer. Genes contain the recipes for the various proteins a cell needs to stay healthy and function normally.
Gene alteration - definition of gene alteration by The ...
mu·ta·tion (myo͞o-tā′shən) n. 1. The act or process of being altered or changed. 2. An alteration or change, as in nature, form, or quality. 3. Genetics a. A change in the nucleotide sequence of the genome of an organism or virus, sometimes resulting in the appearance of a new character or trait not found in the parental type. b. The process by ...
Wealtec Corp. 1885 Meadowvale Way Sparks, NV 89431, USA TEL:+1-775-351-2066 FAX:+1-775-351-2077
Herceptin Dosage Guide - Drugs.com
Patient Selection. Select patients based on HER2 protein overexpression or HER2 gene amplification in tumor specimens [see Indications and Usage (1) and Clinical Studies (14)].Assessment of HER2 protein overexpression and HER2 gene amplification should be performed using FDA-approved tests specific for breast or gastric cancers by laboratories with demonstrated proficiency.
MLL amplification in leukemia - Atlas of Genetics and ...
Duplication or amplification of chromosome band 11q23, including the unrearranged MLL gene, is a recurrent abnormality in therapy-related MDS and AML, and is closely related to mutation of the TP53 gene and to previous therapy with alkylating agents.
PRODUCTS : SHIMADZU (Shimadzu Corporation)
For Research Use Only. Not for use in diagnostic procedures. This page may contain references to products that are not available in your country.
Pathology Solutions | Agilent
We provide trusted answers, together with our customers, through our integrated pathology solutions. Our portfolio includes a full range of world-class products, service and support that meet the individual needs of your lab and enables efficient, cost-effective and accurate diagnosis for cancer patients.
Pathology Outlines - Dedifferentiated liposarcoma
Although originally these tumors were all considered high grade, low grade dedifferentiation is now a recognized phenomenon Low grade dedifferentiation can be histologically indistinguishable from cellular well differentiated liposarcoma; the terminology that is used varies among practicing pathologists